Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:1–11.
   Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–1395.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1314.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108:1132–1138.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009;103:202–209.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. CG97. The management of lower urinary tract symptoms in men: NICE guideline; 2010 May [cited 2017 Aug]. Available from: https://www.nice.org.uk/guidance/cg97
   Google Scholar
• National Institute for Health and Care Excellence. CG171. The management of urinary incontinence in women: NICE guideline; 2013 Sep [cited 2017 Aug]. Available from: https://www.nice.org.uk/guidance/cg171
   Google Scholar
• Solifenacin (Vesicare®) Summary of Product Characteristics. 2013 [cited 2017 Aug]. Available from: https://www.medicines.org.uk/emc/medicine/14900
   Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464–470.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303–310.
   PubMed Web of Science ®Google Scholar
• Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;18(1):CD005429.
   Google Scholar
• Luo D, Liu L, Han P, et al. Solifenacin for overactive bladder: a systematic review and meta-analysis. Int Urogynecol J. 2012;23:983–991.
   PubMed Web of Science ®Google Scholar
• Nazir J, Kelleher C, Aballéa S, et al. Comparative efficacy and tolerability of solifenacin 5 mg/day versus oral antimuscarinic agents in overactive bladder: a systematic literature review and network meta-analysis. Neurourol Urodyn. 2017;1–11. DOI:10.1002/nau.23413
   Web of Science ®Google Scholar
• Aballéa S, Maman K, Thokagevistk K, et al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom. Clin Drug Investig. 2015;35:83–93.
   PubMed Web of Science ®Google Scholar
• Nazir J, Maman K, Neine ME, et al. Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in the United Kingdom. Value Health. 2015;18:783–790.
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–338.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. PMG9. Guide to the methods of technology appraisal 2013: NICE article; 2013 Apr [cited 2017 Aug]. Available from: http://www.nice.org.uk/article/pmg9/chapter/foreword
   Google Scholar
• Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008;11:956–964.
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck PE, Heesakkers J, Berriman S, et al. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int J Clin Pract. 2010;64:584–593.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305.
   PubMed Web of Science ®Google Scholar
• Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics. 2011;29:35–49.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Europe Ltd. Solifenacin. Study 905-CL-015: number and percentage of patients with at least one TEAE, classified by System Organ Class and Preferred Term. Data on file. 2016.
   Google Scholar
• Castro-Diaz D, Miranda P, Sanchez-Ballester F, et al. Assessment of reasons for overactive bladder treatment change [Article in Spanish]. Actas Urol Esp. 2011;35:73–79.
   Web of Science ®Google Scholar
• Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72:389–399.
   PubMed Web of Science ®Google Scholar
• Odeyemi IA, Dakin HA, O’Donnell RA, et al. Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract. 2006;60:949–958.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–295.
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108.
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press; 2016 Sep.
   Google Scholar
• Curtis L, Burns A Personal Social Services Research Unit (PSSRU). Unit Costs of Health and Social Care; 2015 [cited 2017 Aug]. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2015/#sections
   Google Scholar
• Department of Health. NHS reference costs 2014–15; [cited 2017 Aug]. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015
   Google Scholar
• Age UK incontinence. Lille Healthcare Classic Form Regular 1300ml pack of 28; [cited 2017 Aug]. Available from: http://www.ageukincontinence.co.uk
   Google Scholar
• Cardozo L, Thorpe A, Warner J, et al. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2010;106:506–514.
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Europe Ltd. Solifenacin. Mean number of pads/day per incontinence severity level estimated from Study 905-CL-015 data. Data on file. 2016.
   Google Scholar
• Dakin H, Devlin N, Feng Y, et al. The influence of cost-effectiveness and other factors on NICE decisions. Health Econ. 2014;23. DOI:10.1002/hec.3086
   Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65:567–585.
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110:1767–1774.
   PubMed Web of Science ®Google Scholar
• Hart WM, Abrams P, Munro V, et al. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the UK. J Med Econ. 2013;16:1246–1254.
   PubMedGoogle Scholar
• Speakman M, Khullar V, Mundy A, et al. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin. 2008;24:2173–2179.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jönsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodynam. 1998;17:599–611.
   PubMed Web of Science ®Google Scholar
• Herschorn S, Nazir J, Ramos B, et al. Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Can Urol Assoc J. 2017;11:123–130.
   Web of Science ®Google Scholar
• Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder. J Urol. 2003 Mar;169:843–848.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. The guidelines manual Process and methods [PMG6]; 2012 Nov [cited 2017 Aug]. Available from: https://www.nice.org.uk/process/pmg6/chapter/assessing-cost-effectiveness
   Google Scholar